

**A PLATELET-ACTIVATING FACTOR ANTAGONIST INHIBITION OF  
ANGIOGENESIS AND TUMOR GROWTH INDUCED BY BASIC FIBROBLAST  
GROWTH FACTOR**

**Jay D. Hunt, Haydee E. Bazan, Victor L. Marcheselli,  
Julio Alvarez Builla G., and Nicolas G. Bazan**

**Express Mail No. EF199471120**

**File No. Hunt 00M28.1**

**[0001]** This invention pertains to a method to decrease tumor growth by inhibiting basic fibroblast growth factor ("bFGF")-stimulated tumor angiogenesis by treatment with a platelet-activating factor antagonist that binds to intracellular binding sites.

**[0002]** Angiogenesis, the development of new blood vessels, occurs in the normal body processes of development, wound healing, and reproduction. It is a complex process involving many stages, including extracellular matrix remodeling, endothelial cell migration and proliferation, capillary differentiation, and anastomosis. All detectable solid tumors exploit this normal process to supply the needed blood to proliferating tumor cells. Studies have demonstrated that the level of vascularization in a tumor is strongly associated with metastasis in melanoma, breast, and lung carcinomas. See R. Bicknell, "Vascular targeting and the inhibition of angiogenesis," *Annals of Oncology*, vol. 5, pp. 45-50 (1994).

**[0003]** A number of protein growth factors are known to induce angiogenesis, including vascular endothelial growth factor ("VEGF"), epidermal growth factor ("EGF"), insulin-like growth factor-1 ("IGF-1"), acidic fibroblast growth factor ("aFGF"), basic fibroblast growth factor ("bFGF"), tumor necrosis factor-2 ("TNF-2"), hepatocyte growth factor ("HGF"), and platelet-derived growth factor ("PDGF"). See R.E. Friesel *et al.*, "Molecular mechanisms of

angiogenesis: fibroblast growth factor signal transduction," FASEB Journal, vol. 9, pp. 919-925 (1995); M. Jaye *et al.*, "Human endothelial cell growth factor: cloning, nucleotide sequence, and chromosome localization," Science, vol. 233, pp. 541-546 (1986); G. Camussi *et al.*, "Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages," J. Immunol., vol. 158, pp. 1302-1309 (1997); and L. Angelov *et al.*, "Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas," Cancer Research, vol. 59, pp. 5536-5541 (1999).

[0004] These peptide growth factors are known to stimulate angiogenesis using a wide range of differing cellular mechanisms. For example, WEB 2170, a platelet-activating factor ("PAF") antagonist, inhibited angiogenesis stimulated by both HGF and TNF- $\alpha$ , suggesting an intermediary role of PAF, but WEB 2170 did not inhibit angiogenesis stimulated by bFGF. See Camussi *et al.*, 1997; and G. Montrucchio *et al.*, "Nitric oxide mediates angiogenesis induced *in vivo* by platelet-activating factor and tumor necrosis factor- $\alpha$ ," American Journal of Pathology, vol. 151, pp. 557-563 (1997).

[0005] The FGF family of growth factors regulates the proliferation and migration of capillary endothelial cells. The FGF family of growth factors currently includes nine members, of which aFGF and bFGF are considered prototypic. bFGF is produced by tumor cells, diffuses to capillary endothelial cells, and stimulates angiogenesis. See Friesel *et al.*, 1995; and R. Flaumenhaft *et al.*, "Role of extracellular matrix in the action of basic fibroblast growth factor: Matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis," Journal of Cellular Physiology, vol. 140, pp. 75-81 (1989). bFGF is expressed in four forms: an 18-kDa form (155 amino acids), a 22-kDa form (196 amino acids), a 22.5-kDa form (201 amino acids), and a 24-kDa form (210 amino acids). The higher molecular weight forms of bFGF contain the complete 18-kDa amino acid sequence in addition to NH<sub>2</sub>-terminal extensions of varying lengths. See P.L. Lee *et al.*, "Purification and complementary DNA cloning of a receptor for basic fibroblast growth factor," Science, vol. 245, pp. 57-60 (1989).

[0006] Platelet-activating factor (PAF; 1-*O*-alkyl-2-acetyl-*sn*-glycero-3-phosphocholine) is a membrane-derived second messenger that is a potent mediator of inflammatory, ischemic, and immunological responses. PAF is rapidly produced in tissues in response to injury and other forms of stimulation. See N.G. Bazan *et al.*, "Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene," *Proc.Natl.Acad.Sci.USA*, vol. 91, pp. 5252-5256 (1994). Intracellular and cell surface binding sites for PAF have been identified and distinguished by using diverse PAF antagonists that show a preference for one or more of the binding sites. See V.L. Marcheselli *et al.*, "Distinct platelet-activating factor binding sites in synaptic endings and intracellular membranes of rat cerebral cortex," *Journal of Biological Chemistry*, vol. 265, pp. 9140-9145 (1990). Two binding sites found were associated with microsomal intracellular membranes and a third binding site was associated with the synaptosomal membrane (the extracellular plasma membrane). One of the internal microsomal binding sites displays the highest known affinity for PAF.

[0007] Several PAF antagonists have been identified. Most of the antagonists are competitive in nature. The antagonists can be divided into three distinct groups: PAF-related compounds such as CV 3988; synthetic PAF-unrelated compounds such as WEB 2086 and SR 27417; and natural products including BN-52021. See A.L.A. Pires *et al.*, "Long-lasting inhibitory activity of the hetrazepinic BN-50730 on exudation and cellular alterations evoked by PAF and LPS," *Br.J.Pharmacol.*, vol. 113, pp. 994-1000 (1994). A unique PAF antagonist, BN-50730, a hetrazepine, is known to displace PAF from microsomal membranes, but not from the synaptosomal, plasma membrane. See V.L. Marcheselli and N.G. Bazan, "Platelet-activating factor is a messenger in the electroconvulsive shock-induced transcriptional activation of *c-fos* and *zif-268* in hippocampus," *Journal of Neuroscience Research*, vol. 37, pp. 54-61 (1994). Moreover, BN-50730 and WEB 2086, another PAF antagonist, are known to have different dissociation kinetics. See C.L. Silva *et al.*, "Formation of a highly stable complex between BN-50730 [tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-*f*] triazolo-1,2,4 [4,3-*a*] diazepine-1,4] and the platelet-activating factor receptor in rabbit platelet membranes," *Biochemical Pharmacology*, vol. 51, pp. 193-196 (1996).

[0008] Angiogenesis stimulated by tumor necrosis factor (TNF- $\alpha$ ) has been shown to be mediated, at least in part, by platelet-activating factor (PAF) synthesized from monocytes and endothelial cells. See G. Montrucchio *et al.*, "Tumor necrosis factor  $\alpha$ -induced angiogenesis depends on in situ platelet-activating factor biosynthesis," J. Exp. Med., vol. 180, pp. 377-382 (1994). TNF- $\alpha$ -induced angiogenesis was inhibited by WEB 2170, a specific PAF receptor antagonist that binds to the extracellular membrane. Additionally, angiogenesis stimulated by TNF- $\alpha$  was later shown to involve both nitric oxide and PAF. See G. Montrucchio *et al.*, "Nitric oxide mediates angiogenesis induced *in vivo* by platelet-activating factor and tumor necrosis factor- $\alpha$ ," American Journal of Pathology, vol. 151, pp. 557-563 (1997). This study also found that angiogenesis stimulated by bFGF was not inhibited by WEB 2170, leading the authors to conclude that bFGF-stimulated angiogenesis is PAF- independent.

[0009] In a later study, angiogenesis stimulated by hepatocyte growth factor (HGF) was found to be mediated by synthesis of PAF and inhibited by the specific PAF receptor antagonist WEB 2170. See G. Camussi *et al.*, "Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages," Journal of Immunology, vol. 158, pp. 1302-1309 (1997). These researchers also reported that angiogenesis induced by bFGF was not inhibited by WEB 2170.

[0010] We have surprisingly discovered that application of a PAF antagonist, such as "BN-50730" (also reported herein as "LAU-8080") (tetrahydro-4,7,8,10 methyl-1 (chloro-1 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4), to both *in vivo* and *in vitro* tumor models of bFGF-stimulated angiogenesis causes a significant reduction in angiogenesis and tumor growth. We have discovered that the bFGF angiogenic pathway involves PAF. We found that the bFGF angiogenic pathway is inhibited by PAF antagonists that bind to intracellular PAF binding sites.

### Brief Description of Drawings

- [0011] Fig. 1 illustrates the structure of BN-50730 (and "LAU-8080"), a PAF antagonist, that binds to intracellular PAF binding sites.
- [0012] Fig. 2a illustrates the temporal change of tumor volume in mice implanted with subcutaneous PC-3 xenografts under three experimental conditions, including multiple treatments with 30 mg/kg BN-50730 or with 60 mg/kg BN-50730.
- [0013] Fig. 2b illustrates the treatment schedule of mice implanted with subcutaneous PC-3 xenografts used to generate the data in Fig. 2a.
- [0014] Fig. 3a illustrates the differences in tumor weight in mice implanted with orthotopic 201T xenografts under three experimental conditions, including an untreated control, treatment with a placebo, and treatment with 60 mg/kg LAU-8080.
- [0015] Fig. 3b illustrates the treatment schedule of the mice implanted with orthotopic 201T xenografts used to generate the data in Fig. 3a.
- [0016] Fig. 4a illustrates the temporal change in tumor volume in mice implanted with subcutaneous PC-3 xenografts after multiple treatments with 120 mg/kg LAU-8080.
- [0017] Fig. 4b illustrates the treatment schedule of the mice implanted with subcutaneous PC-3 xenografts used to generate the data in Fig. 4a.
- [0018] Fig. 5a illustrates the effect of various concentrations of BN-50730 on *in vitro* cell proliferation of PC-3 cells as measured by [<sup>3</sup>H]thymidine incorporation.
- [0019] Fig. 5b illustrates the effect of 10  $\mu$ M BN-50730 on *in vitro* cell proliferation over time of PC-3 cells as measured by [<sup>3</sup>H]thymidine incorporation.
- [0020] Fig. 5c illustrates the effect of various concentrations of BN-50730 on *in vitro* cell proliferation of 201T cells as measured by [<sup>3</sup>H]thymidine incorporation.
- [0021] Fig. 5d illustrates the effect of 10  $\mu$ M BN-50730 on *in vitro* cell proliferation over time of 201T cells as measured by [<sup>3</sup>H]thymidine incorporation.
- [0022] Fig. 6 illustrates the inhibitory effect of 5  $\mu$ M BN-50730 on *in vitro* cell proliferation as measured by [<sup>3</sup>H]thymidine incorporation of human umbilical vein endothelial cells grown in EGM-2 and EGM growth-factor enhanced media.

[0023] Fig. 7 illustrates the inhibitory effect of 5  $\mu$ M BN-50730 on *in vitro* cell proliferation as measured by [ $^3$ H]thymidine incorporation of human umbilical vein endothelial cells in either 201T-conditioned medium or EGM-2 growth-factor enhanced growth medium.

[0024] Fig. 8a illustrates the effect of 10  $\mu$ M BN-50730 on *in vitro* cell proliferation as measured by [ $^3$ H]thymidine incorporation of human umbilical vein endothelial cells in medium enhanced by a single growth factor.

[0025] Fig. 8b illustrates the effect of 10  $\mu$ M BN-50730 on *in vitro* cell proliferation as measured by [ $^3$ H]thymidine incorporation of human umbilical vein endothelial cells in growth-factor enhanced media that is missing a single growth factor.

[0026] Fig. 9 illustrates the results of a Western blot analysis of cell lysates for bFGF of human umbilical vein endothelial cells (lanes 1 and 2), PC-3 cells (lanes 3 and 4), or 201T cells (lanes 5 and 6) grown in the presence (lanes 2, 4, and 6) or absence (lanes 1, 3, and 5) of BN-50730.

[0027] Fig. 10a illustrates the temporal change in tumor volume in mice implanted with subcutaneous PC-3 xenografts treated with a placebo, with 120 mg/kg LAU-8080, with a 1000 units of IFN- $\alpha$ , and with both LAU-8080 and IFN- $\alpha$ .

[0028] Fig. 10b illustrates the treatment schedule of the mice implanted with subcutaneous PC-3 xenografts used to generate the data in Fig. 10a.

[0029] The present invention provides a new use for the PAF antagonist BN-50730 (or LAU-8080) and other PAF antagonists that bind to the intracellular PAF binding sites. LAU-8080 is the same compound as BN-50730, but is synthesized by a different mechanism. BN-50730 was surprisingly found to inhibit angiogenesis stimulated by bFGF, despite the literature reports that bFGF-stimulated angiogenesis was PAF-independent. Another PAF antagonist that is known to bind to the intracellular PAF binding sites is CV-3988. See V.L. Marcheselli *et al.*, "Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex," J. Biol. Chem., vol. 265, pp. 9140-9145 (1990).

[0030] As used herein, the term "bFGF-active PAF antagonist" refers to a PAF antagonist that binds to the intracellular PAF binding sites and inhibits angiogenesis otherwise stimulated by bFGF.

[0031] The bFGF-active PAF antagonist may be administered to a patient by any suitable means, including parenteral, subcutaneous, intrapulmonary, and intranasal administration. Parenteral infusions include intramuscular, intravenous, intraarterial, or intraperitoneal administration. The bFGF-active PAF antagonist may also be administered transdermally, for example, in the form of a slow-release subcutaneous implant, or orally in the form of capsules, powders, or granules. It may also be administered by inhalation.

[0032] Pharmaceutically acceptable carrier preparations for parenteral administration include sterile, aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. The active therapeutic ingredient may be mixed with excipients that are pharmaceutically acceptable and are compatible with the active ingredient. Suitable excipients include water, saline, dextrose, glycerol and ethanol, or combinations thereof. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, inert gases, and the like.

[0033] The form may vary depending upon the route of administration. For example, compositions for injection may be provided in the form of an ampule, each containing a unit dose amount, or in the form of a container containing multiple doses.

[0034] The bFGF-active PAF antagonist may be formulated into therapeutic compositions as pharmaceutically acceptable salts. These salts include the acid addition salts formed with inorganic acids such as, for example, hydrochloric or phosphoric acid, or organic

acids such as acetic, oxalic, or tartaric acid, and the like. Salts also include those formed from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and organic bases such as isopropylamine, trimethylamine, histidine, procaine and the like.

**[0035]** Controlled delivery may be achieved by admixing the active ingredient with appropriate macromolecules, for example, polyesters, polyamino acids, polyvinyl pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, prolamine sulfate, or lactide/glycolide copolymers. The rate of release of the bFGF-active PAF antagonist may be controlled by altering the concentration of the macromolecule.

**[0036]** Another method for controlling the duration of action comprises incorporating the bFGF-active PAF antagonist into particles of a polymeric substance such as a polyester, peptide, hydrogel, polylactide/glycolide copolymer, or ethylenevinylacetate copolymers. Alternatively, the bFGF-active PAF antagonist may be encapsulated in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, by the use of hydroxymethylcellulose or gelatin-microcapsules or poly(methylmethacrylate) microcapsules, respectively, or in a colloid drug delivery system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.

**[0037]** The term "therapeutically effective amount" as used herein refers to an amount of the bFGF-active PAF antagonist sufficient to decrease angiogenesis and tumor cell proliferation. The term "therapeutically effective amount" therefore includes, for example, an amount of an bFGF-active PAF antagonist sufficient to prevent the growth of the patient's tumor, and preferably to reduce by at least 50%, and more preferably to reduce by at least 90%, the mass of a patient's tumor. The dosage ranges for the administration of the bFGF-active PAF antagonist are those that produce the desired effect. Generally, the dosage will vary with the age, weight, condition, sex of the patient, type of tumor, and degree of tumor development. A person of ordinary skill in the art, given the teachings of the present specification, may readily determine suitable dosage ranges. The dosage can be adjusted by the individual physician in the event of



any contraindications. In any event, the effectiveness of treatment can be determined by monitoring the extent of tumor growth and remission by methods well known to those in the field.

### Example 1

#### *Materials and Methods*

##### *BN-50730 or LAU-8080*

[0038] The structure of the PAF antagonist, tetrahydro-4,7,8,10 methyl-1 (chloro-2 phenyl)-6 (methoxy-4 phenyl-carbomoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4[4,3-*a*]diazepine-1,4 is shown in Fig. 1. This compound, known as BN-50730, was initially obtained from Beaufoure-Ipsen, France. The term "LAU-8080" is used in the examples to refer to a compound obtained from the Universidad de Alcala, Madrid, Spain, with the same structure as BN-50730, but synthesized by a different method than the compound from Beaufoure-Ipsen. See International Application No. WO 01/83440. Thus, in the following examples, the designation of the compound as "BN-50730" or "LAU-8080" is used to identify the source of the compound. In the rest of the specification and claims, the name "BN-50730" is used as the generic name for the PAF antagonist shown in Fig. 1.

[0039] The compound was dissolved in DMSO (dimethyl sulfoxide) and stored at -20°C as a 5.5 mM stock solution.

#### *Cell Lines and Growth Conditions*

[0040] The human prostatic carcinoma cell line PC-3 was grown in RPMI 1640 (Life Technologies, Grand Island, Nebraska) supplemented with 10% fetal bovine serum ("FBS", Life Technologies). The human cell line 201T was established from a poorly differentiated lung adenocarcinoma, as previously described using the method of J.M. Siegfried *et al.*, "Secretion of autocrine growth factors by cultured lung tumors: effects on neoplastic lung epithelial cells," Lung Cancer, vol. 4, pp. 205-209 (1988). See also J.P. Hamide *et al.*, "Percutaneous implantation of non-small cell lung carcinoma: technique and observations," *Academ. Radiol.*,

vol. 4, pp. 629-633 (1997). The cell line was grown in a medium conditioned for 48 hours by the cell line A549 (ATCC CCL-185) containing 1% FBS (HyClone Laboratories, Logan, Utah) as previously described in J. M. Siegfried, "Culture of primary lung tumors using medium conditioned by a lung carcinoma cell line," J.Cell.Biochem., vol. 41, pp. 91-95 (1988). This medium is referred to as CM+1% FBS.

[0041] Human umbilical vein endothelial cells ("HUVEC") were propagated in one of three growth media depending on the experimental conditions. HUVEC were maintained in endothelial basal medium ("EBM-2") (Clonetics, Walkersville, Maryland) supplemented with 2% FBS (Clonetics). HUVEC were also grown in endothelial growth medium ("EGM") (Clonetics), which contained 3 mg/ml (protein content) bovine brain extract, 10 ng/ml EGF (endothelial growth factor), 1  $\mu$ g/ml hydrocortisone, 2% FBS, gentamicin, and amphotericin-B. HUVEC were likewise grown in EGM-2, supplemented with VEGF (vascular epithelial growth factor), R<sup>3</sup>-IGF-1 (long recombinant-3 insulin-like growth factor-1), ascorbic acid, heparin, 2% FBS, EGF, bFGF, gentamicin, and amphotericin-B.

[0042] All cell lines were grown in a humidified incubator in 5% CO<sub>2</sub> at 37°C. Cell monolayers approaching 75% confluency were harvested using the De Larco formulation of trypsin-EDTA (Life Technologies) and were subcultured for serial passage.

#### *Experimental Animals*

[0043] Pathogen-free 4 to 6 week-old male NCr athymic nude mice (Taconic, Germantown, New York) were housed in sterilized, filter-topped cages kept in laminar flow isolators (Forma Scientific, Marietta, Ohio), and fed autoclaved food and water *ad libitum*. Four animals were housed in each cage. Mice were acclimated to the vivarium for one week prior to their use in study protocols. All procedures involving the mice were performed under sterile conditions in a laminar flow hood (Forma Scientific). All studies were approved by the institutional animal care and use committee.

*Tumor Implantation and Growth*

[0044] Human PC-3 prostate cancer cells ( $2 \times 10^6$  cells; American Type Culture Collection CRL-1435) were inoculated subcutaneously into the flanks of nude mice in 0.1 ml HBSS (Hank's balanced salt solution) (Life Technologies). For implantation of orthotopic 201T cells, animals were fully anesthetized in a Harvard small animal anesthesia chamber using nebulized Metafane (Pitman Moore, Inc., Washington Crossing, New Jersey). Intrathoracic injections were performed at the lateral dorsal midaxillary line just inferior to the scapular angle using a 1.2 cm, 27-gauge needle. The needle was advanced through the chest wall into the lung tissue, and the tumor cell inoculum of  $2 \times 10^6$  cells was then dispersed in a final volume of 0.1 ml HBSS/Matrigel (1:1 ratio). Animals were allowed to recover from anesthesia for approximately 10 min under heat lamps to maintain body temperature. The orthotopic implantation technique is further described in Hamide *et al.*, 1997. For tumors implanted subcutaneously, tumors were measured in a blind fashion with dial calipers, and the volume was calculated using the formula  $\frac{1}{2} \pi (W \times L \times H)$ . For orthotopically implanted 201T cells, tumors were detected in these mice by weighing the excised mediastinal block (heart, lung, and tumor if present) and comparing these weights to the mediastinal blocks from litter mates who did not receive tumor implantation.

*In vitro Cell Growth Assays*

[0045] PC-3 cells were exposed to 0, 0.1, 1, 2.5, 5, and 10  $\mu$ M BN-50730 in RPMI medium supplemented with 10% FBS and [ $^3$ H]thymidine (Amersham Life Science, Arlington Heights, Illinois). 201T cells were exposed to 0, 0.1, 1, 2.5, 5, and 10  $\mu$ M BN-50730 in CM +1% FBS supplemented with [ $^3$ H]thymidine. The cells were allowed to propagate for 5 days in the presence of BN-50730 or DMSO, followed by the measurement of acid-perceptible [ $^3$ H]DNA by liquid scintillation counting. PC-3 and 201T cells were also exposed to 10  $\mu$ M BN-50730 for 24, 48, 72 and 144 hours, and cell growth assessed as above.

### *Western Blot Analysis*

[0046] HUVEC, PC-3, and 201T cells were grown to 75% confluency in the appropriate growth media. BN-50730 (5  $\mu$ M) or vehicle (DMSO) was added to each cell line 18 hr prior to cell harvest. Cells were washed three times in phosphate-buffered saline ("PBS") and scraped into Lemely buffer which lacked bromophenol blue and  $\beta$ -mercaptoethanol (0.1 M NaCl, 0.01M Tris-HCl (pH 7.6), 0.001 M EDTA, 1  $\mu$ g/ml aprotinin, 100  $\mu$ g/ml phenylmethylsulfonyl flouride, 2% SDS, and 10% glycerol). The cell suspension was boiled for 10 min and then immediately stored at -20°C. Protein levels were quantified using a Bio-Rad Protein Assay (Bio-Rad, Hercules, California). Protein samples (20  $\mu$ g) were separated through a 10-20% denaturing gradient acrylamide gel in Tris-glycine buffer and transferred to nitrocellulose (Bio-Rad) by electrophoretic blotting. The nitrocellulose was blocked in 0.4% non-fat dry milk and incubated for 1 hr at 4°C with mouse anti-human bFGF monoclonal IgG<sub>1</sub> antibody (3H3, Oncogene Research Products, Cambridge, Massachusetts). Primary antibody was detected using alkaline phosphatase-conjugated goat anti-mouse IgG (Bio-Rad).

### *Statistics*

[0047] Statistical analyses were done on a Macintosh PowerPC G3 using Statview 4.51 (Abacus Concepts, Inc., Berkeley, California). Significance was set at  $p < 0.05$ .

## **Example 2**

### ***Inhibition of Tumor Formation by BN-50703 or LAU-8080***

[0048] Potential anti-angiogenic and anti-tumor effects of the PAF antagonist BN-50730 were tested on human tumor xenografts in the NCr athymic nude mice. Thirty mice were implanted with subcutaneous human prostatic carcinoma cells, PC-3, at day 0, and were randomized into three groups. Mice were treated either with a placebo, 30 mg/kg BN-50730, or 60 mg/kg BN-50730 at days 2, 4, 6, 8, 10, and 12 as shown in the schedule of Fig. 2b. Animals were sacrificed at day 13, 17, 21 and 28, and the volumes of the subcutaneous tumors

were measured using dial calipers and the formula  $\frac{1}{2} \times \pi(W \times L \times H)$  as described in Example 1. A significant dose-dependent reduction in tumor size was seen ( $p < 0.001$ ) (Fig. 2a).

[0049] Another set of mice was randomized into three groups. Two groups were implanted orthotopically with human 201T lung adenocarcinoma cells at day 0. The control, unimplanted group received no treatment. The two implanted groups were treated either with a placebo or with 60 mg/kg LAU-8080. The treatments were given at days 2, 4, 6, 8, 10, and 12 as shown in Fig. 3b; and the animals were sacrificed at day 56. (Fig. 3b). The mediastinal blocks containing the heart, lungs, and tumors (if present) were excised upon necropsy and weighed. The mediastinal blocks were significantly larger in placebo-treated animals as compared to those treated with LAU-8080 ( $p = 0.011$ , Student's t-test). (Fig. 3a). As seen in Fig. 3a, the mediastinal weight of LAU-8080-treated animals was the same as for control litter mates who did not receive tumor cell implantation or drug treatment ( $p = 0.800$ , Student's t-test).

[0050] In a separate experiment to determine the effects of a high dose of LAU-8080 dissolved in 2-hydroxypropyl- $\beta$ -cyclodextran (instead of DMSO) on PC-3 xenografts, mice were treated as shown in Fig. 4b. Tumors were implanted subcutaneously at day 0. The mice were then divided into two groups to receive injections of either a placebo or 120 mg/kg LAU-8080 on days 1, 3, 5, 8, 10, and 12. Mice were sacrificed on days 6, 8, 11, 13, 15, 18, 20, 21, and 25; and the volumes of the tumors were measured as described above. The mice treated with the high dose of LAU-8080 had significantly smaller tumors as compared to the placebo-treated mice ( $p = 0.0001$ , F-test). (Fig. 4a). The tumors in the mice treated with LAU-8080 did not begin to increase in size until after treatment was stopped at day 12.

[0051] BN-50730 (or LAU-8080) significantly reduced the size of subcutaneous and intrathoracic tumors in nude mice. Based on visual observations, there were no apparent side effects in mice treated at any dose of BN-50730.

[0052] Nude mice could be used to test the effects of BN-50730 on other known tumor cells in a procedure similar to that discussed above in Examples 1 and 2. The nude mice would be implanted with commercially available tumor cells and then treated with BN-50730 to determine its effect on tumor size.

### Example 3

#### ***BN-50730 Had Minimal Effect on Tumor Proliferation in vitro.***

[0053] To determine whether if BN-50730 affected the growth of tumor cells *in vitro*, concentration response and time course experiments were performed on the prostatic carcinoma cell line PC-3 and on the lung adenocarcinoma cell line 201T using [<sup>3</sup>H]thymidine incorporation assays. As seen in Fig. 5a, PC-3 cells were not affected by treatment with BN-50730 when treated for 4 days with concentrations of 0.01, 0.1, 1, 2.5, 5, and 10  $\mu$ M BN-50730 ( $p=0.529$  for 10  $\mu$ M, Student's t-test). There was no effect from treatment with 10  $\mu$ M BN-50730 at 1, 2, 3, or 6 days (Fig. 5b;  $p=0.556$ , F-test). This indicated that the *in vivo* decrease in tumor growth was due to an antiangiogenic effect.

[0054] However, a concentration-dependent reduction in growth of 201T cells was observed when treated with the above concentrations of BN-50730 for four days (Fig. 5c,  $p<0.005$  for concentrations at or above 1.0  $\mu$ M, Student's t-test). The six-day time course for 201T cells exposed to 10  $\mu$ M BN-50730 demonstrated that the growth inhibition was manifested after 72 hr of exposure. Although the inhibition in growth was large after 144 hr of exposure, the curves were not statistically different (Fig. 5d,  $p=0.081$ , F-test). This result, seemingly contradictory, was explained by the results presented below in Example 5.

### Example 4

#### ***BN-50730 Inhibits Growth of HUVEC in vitro.***

[0055] Based on the above *in vitro* tumor data, the effect of BN-50730 on tumor growth is believed to result from inhibition of angiogenesis. To test this theory, the effect of BN-50730 on angiogenesis of HUVEC cells was measured using two growth media designed to induce rapid proliferation, EGM or EGM-2. HUVEC growth was measured by [<sup>3</sup>H]thymidine incorporation into DNA. Under both growth conditions, 5  $\mu$ M BN-50730 significantly reduced the growth of HUVEC (Fig. 6,  $p=0.001$ , Student's t-test).

### Example 5

#### ***BN-50730 Inhibits HUVEC Proliferation Stimulated by Tumor-Conditioned Media.***

[0056] As many tumors are known to produce angiogenesis-inducing factors, an experiment was conducted to test for increased proliferation of HUVEC cells exposed to 201T-conditioned medium. 201T cells were allowed to condition basal medium (EBM supplemented with 2% FBS) for 48 hr. This medium does not contain any additional growth factors other than those present in the FBS. As seen in Fig. 7, greater stimulation of HUVEC growth was associated with exposure to medium conditioned by 201T cells as compared to fresh EGM-2 medium. EGM-2 is a medium containing the growth factors bFGF, VEGF, IGF-1, and EGF. As shown in Fig. 7, the stimulation of HUVEC growth in either medium was inhibited by the addition of 5  $\mu$ M BN-50730.

[0057] Based on these results, it is clear that the tumor cell line 201T produces soluble growth factors that induce rapid proliferation of HUVEC, and that the effect of this stimulation can be inhibited by BN-50730, a PAF antagonist that binds to intracellular PAF binding sites. This also explains the inhibition of 201T cells seen in Example 3.

### Example 6

#### ***BN-7030 blocks bFGF-induced Proliferation of HUVEC Cells.***

[0058] To characterize the inhibitory effects of BN-50730 on HUVEC proliferation, a series of growth assays was performed in which growth factors were either added or omitted singly from the growth medium in the presence or absence of BN-50730. The cells were grown in a medium supplemented with [ $^3$ H]thymidine, in either the presence or absence of BN-50730. Cells that proliferate will incorporate [ $^3$ H]thymidine into their DNA. In the first experiment, individual growth factors VEGF, IGF-1, bFGF, or EGF were added to EBM-2 supplemented with 2% FBS. As seen in Fig. 8a, the inhibitory effect of BN-50730 depended on which growth factor was used. A small, but significant ( $p=0.036$ , Student's t-test) reduction in HUVEC growth was observed when 10  $\mu$ M BN-50730 was included in the medium containing VEGF. No difference was seen in the media with either IGF-1 or EGF. However, a larger reduction was

observed in the medium containing bFGF ( $p=0.0002$ ). This experiment supports the hypothesis that different cellular mechanisms use different peptide growth factors.

[0059] In a subsequent experiment, mixtures of the growth factors were analyzed, with only one growth factor absent from the medium, and each of the other three were present, in the presence or absence of 10  $\mu$ M BN-50730. As shown in Fig. 8b, a reduction in growth was observed when the medium lacked only VEGF, IGF-1 or EGF. However, no reduction was seen when bFGF was absent.

[0060] These results show that BN-50730 reduces the growth of HUVEC stimulated by bFGF. BN-50730 inhibited the bFGF pathway that would otherwise stimulate angiogenesis. The data also show that the growth factors VEGF, IGF-1, and EGF do not stimulate angiogenesis using the same PAF pathway as bFGF. Because BN-50730 is a known PAF antagonist that binds to intracellular binding sites, it is now believed that bFGF stimulates angiogenesis using an intracellular PAF-mediated mechanism.

### Example 7

#### ***201T and PC-3 Cell Lines Produce bFGF.***

[0061] To demonstrate that 201T and PC-3 cell lines both produce bFGF, a western blot analysis was performed on cell lysates for the presence of bFGF. The methods were as in Example 1. The results are shown in Fig. 9. Lysates were analyzed from HUVEC cells grown in the presence of DMSO (Lane 1) or 5  $\mu$ M BN-50730 (Lane 2); PC-3 cells grown in the presence of DMSO (Lane 3) or 5  $\mu$ M BN-50730 (Lane 4); and 201T cells grown in the presence of DMSO (Lane 5) or 5  $\mu$ M BN-50730 (Lane 6). Not surprisingly, HUVEC did not produce bFGF. However, both 201T and PC-3 cells produced bFGF in both the presence and absence of BN-50730. This demonstrates that BN-50730 does not inhibit the production of bFGF, but acts through another mechanism.



### Example 8

#### *Comparison of Anti-Tumor Effect of BN-50730 with that of IFN-2 $\alpha$*

[0062] Infantile cutaneous hemangiomas are capillary bed tumors that demonstrate rapid growth during the first year of life. They have been shown to express high levels of the angiogenic factors bFGF and VEGF and low levels of the negative regulatory factor interferon  $\beta$  (IFN- $\beta$ ). See D.R. Bielenberg *et al.*, "Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN- $\beta$ ," *Int.J.Cancer*, vol. 14, pp. 401-408 (1999). IFN- $\beta$  inhibits endothelial cell migration; and when injected around tumors, it damages blood vessels, leading to necrosis. Several types of tumors have been successfully treated with IFN-2 $\alpha$ . See E. Chang *et al.*, "Successful treatment of infantile hemangiomas with interferon-alpha-2 $\beta$ ," *J.Pediatric Hematol. Oncol.*, vol. 19, pp. 237-244 (1997); R.A. Ezekowitz *et al.*, "Interferon alpha-2 $\alpha$  therapy for life-threatening hemangiomas of infancy," *N.Engl.J.Med.*, vol. 326, pp. 1456-1463 (1992); and C.W. White *et al.*, "A treatment of childhood angiomatic disease with recombinant interferon alpha-2 $\alpha$ ," *J. Pediatr.*, vol. 188, pp. 59-66 (1991).

[0063] To compare the potential anti-tumor effect of BN-50730 with the FDA human-approved antiangiogenic compound IFN-2 $\alpha$ , nude mice bearing PC-3 xenografts were treated with either 120 mg/kg BN-50730 ( $n=6$ ), 1,000 U human IFN-2 $\alpha$  ( $n=6$ ) (Sigma Chemical Co., St. Louis, Missouri), 120 mg/kg BN-50730 + 1,000 U human IFN-2 $\alpha$  ( $n=6$ ), or with vehicle alone (Control,  $n=6$ ). Tumors were implanted at day 0. The tumors were allowed to expand to 100 mm<sup>3</sup> before treatment was initiated as shown in the schedule in Fig. 10b. Tumor measurements were begun on day 9. Treatments of the different groups were on days 13, 15, 17, 20, 22, 24, 27, 29, and 31. Tumor measurements were taken on days 13, 16, 20, 24, 27, 31, 37, and 40. As seen in Fig. 10a, each of the treatment groups resulted in significantly smaller tumors as compared to control animals ( $p<0.001$ , F-test). There was no significant difference in the size of tumors in BN-50730-treated mice versus IFN-2 $\alpha$ -treated mice ( $p=0.089$ , F-test). Therefore, based on

these limited preliminary data, BN-50730 appears to have an effectiveness as comparable to that of IFN-2 $\alpha$  on established PC-3 xenografts in nude mice.

[0064] The use of downstream inhibitors of angiogenesis as therapeutic options is an intriguing possibility. Many inhibitors of growth factors or their receptors have been tested for their potential as anti-angiogenesis therapeutic agents. These compounds typically target only one specific growth factor cascade and may lack the broad applicability that second messenger inhibitors, like BN-50730, may possess. Therefore, the combination of BN-50730 with other known antiangiogenic compounds may dramatically increase the efficacy of those agents. Examples of other known antiangiogenic compounds that might prove effective in combination with BN-50730 include WEB 2086, INF-2 $\alpha$ , TNP-470, endostatin, SU 5416, SU 6668, batimistat, angiostatin and celecoxib. See D. Inger *et al.*, "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," *Nature*, vol. 348, pp. 555-7 (1990); M.S. O'Reilly *et al.*, "Endostatin: an endogenous inhibitor of angiogenesis and tumor growth," *Cell*, vol. 88, pp. 277-85 (1997); T.A. Fong *et al.*, "SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types," *Cancer Res.*, vol. 59, pp. 99-106 (1999); A.D. Laird *et al.*, "SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors," *Cancer Res.*, vol. 60, pp. 4152-60 (2000); R.D. Kenagy *et al.*, "The role of plasminogen, plasminogen activators, and matrix methalloproteinases in primate arterial smooth muscle cell migration," *Arterioscler. Thromb. Vasc.Biol.*, vol. 16, pp. 1373-82 (1996); M.S. O'Reilly *et al.*, "Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth," *Cold Spring Harb. Symp. Quant. Biol.*, vol. 59, pp. 471-82 (1994); and J.L. Masferrer *et al.*, "Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors," *Cancer Res.*, vol. 60, pp. 1306-11 (2000).

### Example 9

#### *Effectiveness of LAU-8080 on Other Tumor Types*

[0065] This compound, referred to as either BN-50730 or LAU-8080, should be useful in treating any tumor that uses bFGF-stimulated angiogenesis, including but not limited to, carcinomas of the lung, breast, colon, stomach, pancreas, skin, uterus, cervix, vagina penis, mouth, larynx, esophagus, liver, kidney or prostate. The compound may also be useful for treating sarcomas, such as soft tissue sarcomas of the muscle or connective tissue, or osteosarcomas. The compound may also be effective against tumors of neurological origin, such as neuroblastomas and glioblastomas and for tumors of neuroectodermal origin such as neuroblastomas. Further, the compound may be effective against metastatic lesions from each of the above tumor types. Because angiogenesis is an important component of the etiology of lymphomas and leukemias in the bone marrow, the compound can also be effective against liquid tumors including, but not limited to, Hodgkin's disease, non-Hodgkin's lymphoma, B-cell lymphomas, T-cell lymphomas, acute lymphocytic leukemia, chronic myloid leukemia, and acute myloid leukemia. Additionally, the compound may be useful for shrinking non-malignant tumors that depend on bFGF-stimulated angiogenesis for growth.

[0066] The effectiveness of this compound on the above tumor types can be tested by methods known to those of ordinary skill in the art. A representative tumor cell line will be obtained from the ATCC and expanded through serial passage using standard cell culture techniques. Following expansion, the cells will be implanted into the appropriate location in athymic nude (nu/nu) mice. The tumors will be allowed to grow to a volume of about 100 mm<sup>3</sup>, as determined by the method described above in Example 1. The mice will then be randomized into at least two groups. One group, the control, will receive a placebo injection; the other group will receive daily injections of LAU-8080. The tumors will be measured daily. A significant reduction in the size of tumor in the treated mice group over the control group will indicate that LAU-8080 is effective in this tumor type.

[0067] The complete disclosures of all references cited in this specification are hereby incorporated by reference. Also incorporated by reference is the full disclosure of each of the following documents: J.D. Hunt *et al.*, "A Platelet-Activating Factor Antagonist, BN-50730, Inhibits Basic Fibroblast Growth Factor-Induced Human Umbilical Vein Endothelial Cell Proliferation and Tumor Xenograft Expansion in Athymic Nude Mice," submitted to Cancer, on September 27, 2000; and J.D. Hunt *et al.*, "The Platelet-Activating Factor (PAF) Antagonist BN-50730 Inhibits Angiogenesis," Proceedings of the American Association for Cancer Research: Cell and Tumor Biology, vol. 41, abstract 4099 (2000). In the event of an otherwise irreconcilable conflict, however, the present specification shall control.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
21